Public bodyUnited Statesmedicalcountermeasures.gov/barda
The Biomedical Advanced Research and Development Authority (BARDA) is a U.S. government agency within the Department of Health and Human Services, specifically under the Administration for Strategic Preparedness and Response. It focuses on advancing the research, development, and procurement of medical countermeasures to protect against public health emergencies, including pandemics, bioterrorism, and chemical, biological, radiological, and nuclear threats.
BARDA provides funding through contracts, grants, and other mechanisms to support the development of vaccines, therapeutics, diagnostics, and manufacturing technologies. It bridges the gap between early-stage research and commercial-scale production, often partnering with private companies, academic institutions, and other organizations. The agency operates primarily within the United States but engages in international collaborations to enhance global health security.
As a key component of U.S. national preparedness strategy, BARDA plays a central role in the biopharmaceutical and life sciences industry by accelerating innovation in medical products. Its activities include supporting specialized facilities, such as lipid innovation centers, to ensure rapid response capabilities during health crises. BARDA is fully government-owned and funded, positioning it as a critical public body rather than a commercial entity.
None yet. When a new project in the record names BARDA as owner, partner or investor, it shows here.
First GMP batch of plant-derived cholesterol produced at the new Tippecanoe facility; full capacity planned by mid-2027 to support LNP-based therapies.
